Cargando…
Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
SIMPLE SUMMARY: Tyrosine kinase inhibitor (TKI) therapy is often taken indefinitely by chronic myeloid leukemia (CML) patients. However, little is known about the long-term or under-reported TKI side effects due to limited longitudinal clinical data on these relatively new drugs. We utilize novel cr...
Autores principales: | Mehra, Nidhi, Varmeziar, Armon, Chen, Xinyu, Kronick, Olivia, Fisher, Rachel, Kota, Vamsi, Mitchell, Cassie S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563938/ https://www.ncbi.nlm.nih.gov/pubmed/36230609 http://dx.doi.org/10.3390/cancers14194686 |
Ejemplares similares
-
Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis
por: Kronick, Olivia, et al.
Publicado: (2023) -
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia
por: Mohanavelu, Prahathishree, et al.
Publicado: (2021) -
Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors
por: Kong, Jee Hyun, et al.
Publicado: (2020) -
Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022) -
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)